FDA grants fast track status to Cardiff’s colorectal cancer drug
Click to view quick news summary (Spoiler)
The FDA granted Fast Track designation to Cardiff Oncology's onvansertib with FOLFIRI/bevacizumab in first-line RAS-mutated metastatic colorectal cancer.
SAN DIEGO, Published Nov 16 -- Cardiff Oncology Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation to onvansertib (Synonyms: NMS-1286937; NMS-P937) in combination with FOLFIRI/bevacizumab for first-line treatment of adult patients with KRAS- or NRAS-mutated metastatic colorectal cancer.
The designation is supported by data from the company’s ongoing randomized Phase 2 CRDF-004 trial. The proposed Phase 3 regimen of 30 mg onvansertib combined with FOLFIRI/bevacizumab achieved a 72.2% confirmed objective response rate, compared with 42.1% for FOLFIRI/bevacizumab alone in the intent-to-treat population, according to a press release statement.
As of September 28, 2026, median progression-free survival had not been reached in the 30 mg arm, compared with approximately 11 months in the combined standard-of-care arms. All patients remaining in the 30 mg arm have been on treatment for at least 21 months.
Onvansertib is an oral PLK1 inhibitor. The company stated that patients with RAS-mutated metastatic colorectal cancer have no first-line therapies specifically approved for their disease.
Fast Track is an FDA program designed to facilitate development and expedite review of drugs intended to treat serious conditions and address unmet medical needs. The designation may allow for more frequent meetings with the FDA and, if criteria are met, eligibility for Accelerated Approval and Priority Review. Fast Track designation does not alter approval standards.
Cardiff Oncology also received FDA Orphan Drug Designation for onvansertib for treatment of chronic myelomonocytic leukemia and small cell lung cancer in October and November 2026.
Colorectal cancer is among the most commonly diagnosed cancers in the United States, with approximately 150,000 new cases annually. Mutations in KRAS or NRAS genes occur in approximately 52% of patients with metastatic colorectal cancer.